...
首页> 外文期刊>Archives of Iranian medicine >Precancerous conditions after H. pylori eradication: A randomized double blind study in first degree relatives of gastric cancer patients
【24h】

Precancerous conditions after H. pylori eradication: A randomized double blind study in first degree relatives of gastric cancer patients

机译:幽门螺杆菌根除后的癌前状况:胃癌患者一级亲属的随机双盲研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Regression of precancerous lesions after H. pylori eradication remains controversial. This study evaluates the change and topography in first degree relatives (FDR) of gastric cancer (GC) patients following H. pylori eradication. METHODS: Participants underwent endoscopy with antrum and corpus histological examinations. Subjects with pangastritis were randomly allocated to placebo or eradication therapy and followed over 41/2 years. RESULTS: Among 989 evaluated FDR, we excluded 468 patients as follows: 108 had macroscopic lesions, 243 had no evidence of any H. pylori infection, and 117 were excluded for other reasons. The remaining subjects (n = 521) were allocated to therapy (group A, n = 261) or placebo (group B, n = 260) groups. Interim analysis of 403 subjects (201 placebo, 202 therapy) showed regression of atrophy (60 out of 97 in the antrum and 37 out of 104 in the corpus) in H.pylori-eradicated versus regression of atrophy (57 out of 184 in the antrum and 23 out of 173 in the corpus) in non-H.pylori-eradicated cases over 21/2 years (P<0.0001). No regression of intestinal metaplasia (IM) occurred in the antrum and corpus of treated subjects over 41/2 years. However, progression of IM occurred in the antrum in 17 out of 90 patients in the non-H. pylori-eradicated versus 4 out of 68 H. pylori-eradicated subjects after 41/2 years (P<0.05). CONCLUSION: Eradication of H. pylori is associated with regression of gastric atrophy but not IM, even in its early stages. Gastric atrophy and IM in the antrum have shown more rapid progression in cases not treated for H. pylori infection (over 41/2 years follow-up) compared to H. pylori-eradicated cases.
机译:背景:幽门螺杆菌根除后癌前病变的消退仍存在争议。本研究评估了根除幽门螺杆菌后胃癌(GC)患者一级亲属(FDR)的变化和地形。方法:对参加者进行内窥镜检查,进行窦腔和体组织学检查。患有胃炎的受试者被随机分配接受安慰剂或根除治疗,并随访41/2年。结果:在989个评估的FDR中,我们按以下方式排除了468例患者:108例有宏观病变,243例无幽门螺杆菌感染迹象,117例因其他原因被排除。其余受试者(n = 521)被分配至治疗组(A组,n = 261)或安慰剂(B组,n = 260)。对403名受试者(201例安慰剂,202种疗法)进行的中期分析显示,幽门螺杆菌根除后萎缩的消退(97例中有60例,体中104例中的37例)与萎缩的消退(184例中184例中的57例)有关。在21/2年内未根除幽门螺杆菌的病例中,胃窦和胃173例中有23例(P <0.0001)。在接受治疗的受试者的胃窦和胃体中,在41/2年内未发生肠化生(IM)退化。然而,在非H型患者中,有90例患者中有17例在胃窦部发生IM进展。在41/2年后,幽门螺杆菌根除的患者与68例幽门螺杆菌根除的受试者中的4位相比(P <0.05)。结论:根除幽门螺杆菌与胃萎缩的消退有关,但与IM无关,即使在早期也是如此。与根除幽门螺杆菌的病例相比,未接受幽门螺杆菌感染的病例(超过41/2年的随访)胃窦萎缩和IM表现出更快的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号